title: Endometriosis: alternative methods of medical treatment.
abstract: Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although in most women a combination of both treatments is required. Long-term medical treatment is usually needed in most women. Unfortunately, in most cases, pain symptoms recur between 6 months and 12 months once treatment is stopped. The authors conducted a literature search for English original articles, related to new medical treatments of endometriosis in humans, including articles published in PubMed, Medline, and the Cochrane Library. Keywords included "endometriosis" matched with "medical treatment", "new treatment", "GnRH antagonists", "Aromatase inhibitors", "selective progesterone receptor modulators", "anti-TNF α", and "anti-angiogenic factors". Hormonal treatments currently available are effective in the relief of pain associated to endometriosis. Among new hormonal drugs, association to aromatase inhibitors could be effective in the treatment of women who do not respond to conventional therapies. GnRH antagonists are expected to be as effective as GnRH agonists, but with easier administration (oral). There is a need to find effective treatments that do not block the ovarian function. For this purpose, antiangiogenic factors could be important components of endometriosis therapy in the future. Upcoming researches and controlled clinical trials should focus on these drugs.
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Leticia
authors.initials: L
authors.lastname: Muñoz-Hernando
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Jose L
authors.initials: JL
authors.lastname: Muñoz-Gonzalez
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Marqueta-Marques
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Alvarez-Conejo
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Tejerizo-García
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Gregorio
authors.initials: G
authors.lastname: Lopez-Gonzalez
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Carlos Haya, Malaga, Spain.
authors.forename: Emilia
authors.initials: E
authors.lastname: Villegas-Muñoz
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Son Llatzer, Palma de Mallorca, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Martin-Jimenez
authors.affiliation: Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Jesús S
authors.initials: JS
authors.lastname: Jiménez-López
keywords: GnRH antagonists; anti-TNF-α; antiangiogenic factors; aromatase inhibitors; endometrial tissue; hormonal treatments; pharmacological treatment options; selective progesterone receptor modulators